Cancer Cachexia: What is Known about its Etiology and what Should be the Current Treatment Approach?

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5111-5115

  Van Halteren, H K ^a   Bongaerts, G P A ^b   Wagener, D J Th ^b  

^a Oosterschelde Hospital   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anorexia; Cachexia; Cancer; Eicosapentanoic acid; Glucocorticoids; Gluconeogenesis; Progestagens

Indexed keywords

CALCIUM; GESTAGEN; GLUCOCORTICOID; ICOSAPENTAENOIC ACID; MEDROXYPROGESTERONE ACETATE; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUNSATURATED FATTY ACID; PREDNISONE; THALIDOMIDE;

ABDOMINAL CRAMP; ANOREXIA; BODY WEIGHT; CACHEXIA; CANCER; CANCER CACHEXIA; CATABOLISM; DOSE RESPONSE; HUMAN; HYPERCALCEMIA; ILEUS; LEAN BODY WEIGHT; METABOLIC DISORDER; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; STEATORRHEA; WEIGHT REDUCTION;

CACHEXIA; HUMANS; NEOPLASMS;

EID: 0842278699     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. De Wijs WD, Begg C, Lavin PT, Band PR and Bennett JM: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-7, 1980.
2. Oveson L, Hannibal J and Mortensen EL: The interrelationship of weight loss, dietary intake and quality of life in ambulatory patients with cancer of lung, breast, and ovary. Nutr Cancer 19: 159-67, 1993
3. Neuenschwander H and Bruera E: Asthenia-cachexia. In: Bruera E, Higginson I, editors. Cachexia-anorexia in Cancer Patients. Oxford: Oxford University Press 57-75, 1996.
4. Bruera E: Anorexia, cachexia and nutrition. Br Med J 315: 1219-22, 1997.
5. Marks DL, Ling N and Cone RD: Role of the central melanocortin system in cachexia. Cancer Res 61: 1432-8, 2001.
6. Wisse BE, Frayo RS, Schwartz MW and Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142: 3292-3301, 2001.
7. Lechan RM and Tatro JB: Hypothalamic melanocortin signalling in cachexia. Endocrinology 142: 3288-91, 2001.
8. Hyltander A, Drott C, Komer U and Lundholm K: Elevated energy expenditure in cancer patients with solid tumors. Eur J Cancer 27: 9-15, 1991.
9. Moley JF, Aamodt R, Rumble W, Kaye W and Norton JA: Body cell mass in cancer bearing and anorectic patients. J Parenter Enteral Nutr 11: 219-22, 1987.
10. Preston T, Fearon KCH, Robertson I, East BW and Calman KC: Tissue loss during severe wasting in lung cancer patients. In: K.J. Ellis, S. Yamasura, and W.D. Morgan (eds.), In Vivo Body Composition Studies, pp. 60-9 London: Institute of Physical Sciences in Medicine, 1987.
11. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R and Lundholm K: Role of endogenous tumor necrosis factor alpha and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 51: 415-21, 1991.
12. Haumer J, Petruschke T, Russ M, Rohrig K and Eckel J: Effects of tumor necrosis factor alpha on glucose transport and lipid metabolism of newly differentiated human fat cells in cell culture. Diabetologica 38: 764-71, 1995.
13. Llovera M, Lopez-Soriano FJ and Argiles JM: Effect of tumor necrosis factor alpha on muscle protein turnover in female Wistar rats. J Natl Cancer Inst 85: 1334-9, 1993.
14. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO and Fisher JE: Interaction between corticosterone and tumor necrosis factor stimulated breakdown in rat skeletal muscle, similar to sepsis. Surgery 108: 460-6, 1990.
15. Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H et al: Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1: 1353-8, 1995.
16. Molotkow A, Satoh M and Tohyama C: Tumor growth and food intake in interleukin-6-gene knock-out mice. Cancer Lett 132: 187-92, 1998.
17. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K and Svanberg E: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57B1 background and eicosanoid-dependent cachexia. Cancer Res 60: 5488-93, 2000.
18. Emilie D: Adminstration of an interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma; effect on lymphoma growth and on B clinical symptoms. Blood 84: 2472-9, 1994.
19. Tisdale M: Biology of cancer cachexia. J Natl Cancer Inst 89: 1763-73, 1997.
20. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H et al: Evidence for tumor necrosis factor/cachectin production in cancer. Lancet 2: 1229-32, 1987.
21. Saarinen UM, Koskelo EK, Teppo AM and Siimes MA: Tumor necrosis factor in children with malignancies. Cancer Res 50: 592-5, 1990.
22. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G et al: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 50: 555-63, 1987.
23. Socher SH, Martinez D, Craig JB, Kuhn J and Oliff A: Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 80: 595-8, 1988.
24. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D et al: Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 56: 803-8, 1987.
25. Strassman G, Fong M, Kenney JS and Jacob CO: Evidence for involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 89: 1681-4, 1992.
26. Soda K, Kawakami M, Kashii K and Miyata M: Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 62: 332-6, 1995.
27. Beck SA and Tisdale MJ: Production of lipolytic and proteolytic factors by a murine tumor producing cachexia in the host. Cancer Res 47: 5919-23, 1987.
28. Tisdale MJ and Beck SA: Inhibition of tumor-induced lipolysis in vitro and cachexia and tumor growth in vivo by eicosapentanoic acid. Biochem Pharmacol 41: 103-7, 1991.
29. Groundwater P, Beck SA, Barton C, Adamson C, Ferrier IN and Tisdale MJ: Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 62: 816-21, 1990.
30. Beck SA, Mullingan HD and Tisdale MJ: Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 82: 1922-6, 1990.
31. Todorov PT, Cariuk P, McDevitt TM, Coles B, Fearon K and Tisdale M: Characterization of a cancer cachectic factor. Nature 379: 739-42, 1996.
32. Hirai K, Hussey HJ, Barber MD, Price SA and Tisdale MJ: Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58: 2359-65, 1998.
33. Tisdale MJ: Cancer anorexia and cachexia. Nutrition 17: 438-42, 2001.
34. Todorov PT, McDevitt TM, Cariuk P, Coles B, Deacon M and Tisdale MJ: Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 56: 1256-61, 1996.
35. Tisdale MJ: The Cancer Cachectic Factor. Supp Care Cancer 11: 73-8, 2003.
36. Cabal-Manzano R, Bhargava P, Torres-Duarte A, Marshall J, Bhargava P and Wainer IW: Proteolysis-inducing factor is expressed in tumors of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 84: 1599-601, 2001.
37. Holm E, Hagmüller E and Staedt U: Substrate balances across colonic carcinomas in humans. Cancer Res 55: 1373-8, 1995.
38. Holroyde C, Gabuzda TG, Putnam RC, Paul P and Reichard GA: Altered glucose metabolism in metastatic carcinoma. Cancer Res 35: 37104, 1975.
39. Holroyde CP, Axelrod RS, Skutches CL, Haff AC, Paul P and Reichard GA: Lactate metabolism in patients with metastatic colorectal cancer. Cancer Res 39: 4900-04, 1979.
40. Holroyde CP, Skutches CL, Boden G and Reichard GA: Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res 44: 5910-13, 1984.
41. Bongaerts GPA, van Halteren HK, Verhagen CAM and Wagener DJTh: Gluconeogenetic energy dissipation: the dynamic force towards cancer cachexia. Submitted
42. Koretz RL: Parenteral nutrition: is it oncologically logical? J Clin Oncol 2: 534-8, 1984.
43. Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A et al: Guidelines on artificial nutrition versus hydration in terminal cancer patients. Nutrition 12: 163-7, 1996.
44. Evans WK, Makuch R, Clamon GH, Feld K, Weiner RS, Moran E et al: Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 45: 3347-53, 1985.
45. Ng EH and Lowry SF: Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 5: 161-84, 1991.
46. Chlesbowski RT: Critical evaluation of the role of nutritional support with chemotherapy. Cancer 55: 268-76, 1985.
47. Klein S, Kinney J, Jeejeebhoy K, Alpers D, Hellerstein M, Murray M et al: Nutrition support in clinical practice: review of published data and recommendations for future research. Summary of a conference sponsored by the National Institutes of Health, American Society for Clinical Nutrition. J Parenter Enteral Nutr 21: 133-56, 1997.
48. Sikora SS, Riberion U, Kane JM III, Landreneau RJ, Lembersky B and Posner MC: Role of nutrition support during induction chemoradiation therapy in esophageal cancer. J Parenter Enteral Nutr 22: 18-21, 1998.
49. Gagnon B and Bruera E: A review of the drug treatment of cachexia associated with cancer. Drugs 55: 675-688, 1998.
50. Fainsinger R: Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson I, eds. Cachexia-anorexia in Cancer Patients. Oxford, England: Oxford University Press 128-140, 1996.
51. Mantovani G, Maccio A, Massa E et al: Managing cancer-related anorexia/cachexia. Drugs 61: 499-514, 2001.
52. Nelson KA: The cancer anorexia-cachexia syndrome. Semin Oncol 27: 64-68, 2000.
53. Argiles JM, Meijsing SH, Pallares-Trujillo J et al: Cancer cachexia: A therapeutic approach. Med Res Rev 21: 83-101, 2001.
54. Bruera E: Pharmacological treatment of cachexia: Any progress? Support Care Cancer 6: 109-113, 1998.
55. Loprinzi CL, Ellison NM, Schaid DJ et al: Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82: 1127-1132, 1990.
56. Loprinzi CL, Michalak JC, Schaid DJ et al: Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11: 762-767, 1993.
57. Bruera E, Macmillan K, Kuehn N et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66: 1279-1282, 1990.
58. Feliu J, Gonzalez-Baron M, Berrocal A et al: Treatment of cancer anorexia with megestrol acetate: Which is the optimal dose? J Natl Cancer Inst 83: 449-450, 1991.
59. Tchekmedyian NS, Hickman M, Siau et al: Megestrol acetate in cancer anorexia and weight loss. Cancer 69: 1268-1274, 1992.
60. Loprinzi CL, Schaid DJ, Dose AM et al: Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11: 152-154, 1993.
61. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M and Santona MC: Cytokine involvement in cancer anorexia-cachexia: Role of megestrol acetate and medroxyprogesterone acetate on cytokine down regulation and improvement of clinical symptoms. Crit Rev Oncog 9: 99-106, 1998.
62. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P and Amadori D: High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 12: 289-300, 2001.
63. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ and Fearon KCH: Effect of oral eicosapentanoic acid on weight loss in patients with pancreatic cancer. Nutrition and Cancer 36: 177-84, 2000.
64. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC et al: The effect of polyunsaturated acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12 suppl. 1: S27-S30, 1996.
65. Barber MD, Wigmore SJ, Ross JA and Fearon KCH: Eicosapentanoic acid attenuates cachexia associated with pancreatic cancer. Prostaglandins Leukotrienes Essent Fatty Acids 57: 204, 1997.
66. Barber MD, Ross JA, Voss AC, Tisdale MJ and Fearon KCH: The effect of an oral nutritional supplement enriched with fish oil on weight loss in patients with pancreatic cancer. Br J Cancer 81: 80-86, 1999.
67. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC and Kalfarentzos F: Dietary omega-3 polyunsatuated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. Cancer 15: 395-402, 1998.
68. Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G et al: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 1: 129-34, 2003.
69. Barber MD and Fearon KCH: Tolerance and incorporation of a high-dose eicosapentanoic acid diester emulsion by patients with pancraetic cancer cachexia. Lipids 36: 347-51, 2001.
70. Lissoni P, Paolorossi F, Tancini G et al: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32: 1340-3, 1996.
71. Lissoni P, Paolorossi F, Ardizzoia A et al: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 23: 15-19, 1997.
72. Bruera E, Neumann CM, Pituskin E et al: Thalidomide in patients with cachexia due to terminal cancer: Preliminary report. Ann Oncol 10: 857-859, 1999.
73. Wigmore SJ, Falconer JS, Plester CE et al: Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 72: 185-188, 1995.
74. McMillan DC, Wigmore SJ, Fearon KC et al: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79: 495-500, 1999.
75. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG and Boyd JH: Erythropoietin reduces anemia and transfusions. Cancer 86: 2362-7, 1999.
76. Demetri GD, Kris M, Wade J, Degos L and Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-25, 1998.
77. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tcheckmedyian S and Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-34, 1997.
78. Klaesson S, Ringdén O, Ljungman P, Lönnquist B and Wennberg L: Reduced blood transfusion requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplantation 13: 397-402, 1994.
79. van Halteren HK, Bongaerts GPA, Verhagen CAM, Kamm YJL, Willems JL, Grutters J et al: Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model. Submitted
80. Daneryd P, Svanberg E, Körner U, Lindholm E, Sandström R, Brevinge H et al: Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58: 5374-9, 1998.
81. Csáki C, Ferencz T, Schuler D and Borsi JD: Recombinant human erythropoietin in the prevention of chemotherapy-induced anemia in children with malignant solid tumors. Eur J Cancer 34: 364-7, 1998.